On September 17, the Kursk enterprise solemnly opened a new site for the production of import-substituting anti-asthmatic agents (pulmo powders).
The total cost of the project is more than 1.9 billion rubles. The implementation of this investment project will add 14 more products to the nomenclature of manufactured medicines and increase production output in total by more than 5.4 million packages per year.
Moreover, 134 new high-performance jobs have been created here. With full output, Pharmstandard-Leksredstva will become Russia’s main manufacturer of preparations for the treatment of obstructive airway diseases, in particular bronchial asthma.
The company makes a significant contribution to the development of the regional economy, ranking top third in the region in terms of production volumes, being one of the main employers and taxpayers. Over the past five years, the company allocated about 4 billion rubles to fixed assets and started mass production of 63 new medicines.
The launch of the new site enables the Kursk plant to continue implementing the import substitution program. In its framework, it is planned to replace foreign medicines for the treatment of the bronchopulmonary system diseases. Among them, there are drugs from the list of vital and essential medicines: Formisonide-nativ, Formoterol-nativ, Salticazon-nativ, Tiotropium-nativ and others.